Abiplatin

Main information

  • Trade name:
  • Abiplatin 0.5 mg/mL Solution for injection
  • Dosage:
  • 0.5 mg/mL
  • Pharmaceutical form:
  • Solution for injection
  • Units in package:
  • Bottle, glass, amber, 20 mL
  • Class:
  • Prescription
  • Prescription type:
  • Prescription
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug
  • Manufactured by:
  • Heraeus Deutschland GmbH & Co. KG

Documents

Localization

  • Available in:
  • Abiplatin 0.5 mg/mL Solution for injection
    New Zealand
  • Language:
  • English

Other information

Status

  • Source:
  • Medsafe - Medicines Safety Authority - New Zealand
  • Authorization number:
  • 3834
  • Authorization date:
  • 01-11-1984
  • Last update:
  • 27-09-2017

18-5-2018

Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy

Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy

Early reviews found patients in the monotherapy arms of both trials with PD-L1 low status had decreased survival compared to patients who received cisplatin- or carboplatin-based chemotherapy.

FDA - U.S. Food and Drug Administration

There are no news related to this product.